Stock listing
Frankfurt:ER4 Emergent BioSolutions Inc. Aktie
German listing (Frankfurt) of Emergent BioSolutions Inc. · home listing NYSE:EBS
Follow Emergent BioSolutions Inc. into a list and get an email when it puts out news.
Share price · FWB:ER4
€4.62 EUR -0.42 (-8.4%)
Close on Nov 20, 2026
- Day range
- €4.62 – €4.62 EURNov 20, 2026
- Market cap
- €237.0M EURAt the close on Nov 20, 2026 · price × 51.27M shares outstanding
- 52-week range
- €3.80 – €11.81 EURLowest and highest trades, Nov 21, 2025 – Nov 20, 2026
- Traded on an average day
- €1,388 EURMedian day 0 shares · 44 days with no trades · last 3 months, Aug 20, 2026 – Nov 6, 2026

Prices by listing
| Listing | Last | Change | Volume | Open | High | Low | Previous close | Price from |
|---|---|---|---|---|---|---|---|---|
| NYSE:EBS · Home | $5.05 USD | -0.45 (-8.2%) | 1,389,025 | $5.08 | $5.24 | $4.981 | $5.50 | Close on Nov 20, 2026 |
| LSE:0IGA | $5.07 USD | -0.01 (-0.2%) | 336 | $5.14 | $5.23 | $4.96 | $5.081 | Close on Nov 20, 2026 |
| Frankfurt:ER4 | €4.622 EUR | -0.423 (-8.4%) | — | €4.622 | €4.622 | €4.622 | €5.045 | Close on Nov 20, 2026 |
Daily closes
Last 3 months, Aug 20, 2026 – Nov 6, 2026 · FWB:ER4 · EUR, adjusted for splits
| Day | Close | Change | % | Open | High | Low | Volume |
|---|---|---|---|---|---|---|---|
| €5.142 | -0.106 | -2.0% | €5.142 | €5.142 | €5.142 | 0 | |
| €5.248 | -0.239 | -4.4% | €5.248 | €5.248 | €5.248 | 3,926 | |
| €5.487 | -0.882 | -13.8% | €5.487 | €5.487 | €5.487 | 3,926 | |
| €6.369 | +0.347 | +5.8% | €4.897 | €6.426 | €4.896 | 0 | |
| €6.022 | -0.304 | -4.8% | €6.022 | €6.022 | €6.022 | 0 | |
| €6.326 | +0.048 | +0.8% | €6.326 | €6.326 | €6.326 | 2,254 | |
| €6.278 | +0.379 | +6.4% | €6.278 | €6.278 | €6.278 | 600 | |
| €5.899 | +0.26 | +4.6% | €5.899 | €5.899 | €5.899 | 0 | |
| €5.639 | +0.081 | +1.5% | €5.639 | €5.639 | €5.639 | 0 | |
| €5.558 | +0.092 | +1.7% | €5.558 | €5.558 | €5.558 | 0 | |
| €5.466 | +0.068 | +1.3% | €5.466 | €5.466 | €5.466 | 0 | |
| €5.398 | -0.166 | -3.0% | €5.398 | €5.398 | €5.398 | 0 | |
| €5.564 | -0.056 | -1.0% | €5.564 | €5.564 | €5.564 | 0 | |
| €5.62 | -0.061 | -1.1% | €5.62 | €5.62 | €5.62 | 0 | |
| €5.681 | -0.656 | -10.4% | €5.681 | €5.681 | €5.681 | 0 | |
| €6.337 | +0.258 | +4.2% | €6.337 | €6.337 | €6.337 | 0 | |
| €6.079 | -0.029 | -0.5% | €6.079 | €6.079 | €6.079 | 0 | |
| €6.108 | -0.057 | -0.9% | €6.108 | €6.108 | €6.108 | 0 | |
| €6.165 | -0.125 | -2.0% | €6.165 | €6.165 | €6.165 | 0 | |
| €6.29 | +0.234 | +3.9% | €6.295 | €6.295 | €6.206 | 200 | |
| €6.056 | -0.166 | -2.7% | €6.056 | €6.056 | €6.056 | 0 | |
| €6.222 | +0.054 | +0.9% | €6.245 | €6.25 | €6.142 | 200 | |
| €6.168 | -0.402 | -6.1% | €6.168 | €6.168 | €6.168 | 0 | |
| €6.57 | -0.171 | -2.5% | €6.564 | €6.604 | €6.525 | 100 | |
| €6.741 | +1.106 | +19.6% | €5.654 | €6.758 | €5.654 | 814 | |
| €5.635 | -0.172 | -3.0% | €5.635 | €5.635 | €5.635 | 0 | |
| €5.807 | -0.241 | -4.0% | €5.807 | €5.807 | €5.807 | 0 | |
| €6.048 | +0.081 | +1.4% | €6.048 | €6.048 | €6.048 | 0 | |
| €5.967 | +0.069 | +1.2% | €5.967 | €5.967 | €5.967 | 0 | |
| €5.898 | +0.052 | +0.9% | €5.901 | €5.901 | €5.879 | 100 | |
| €5.846 | +0.101 | +1.8% | €5.846 | €5.846 | €5.846 | 0 | |
| €5.745 | -0.033 | -0.6% | €5.745 | €5.745 | €5.745 | 0 | |
| €5.778 | +0.173 | +3.1% | €5.778 | €5.778 | €5.778 | 0 | |
| €5.605 | -0.289 | -4.9% | €5.605 | €5.605 | €5.605 | 0 | |
| €5.894 | -0.188 | -3.1% | €5.894 | €5.894 | €5.894 | 0 | |
| €6.082 | +0.225 | +3.8% | €6.082 | €6.082 | €6.082 | 0 | |
| €5.857 | +0.381 | +7.0% | €5.857 | €5.857 | €5.857 | 0 | |
| €5.476 | +0.031 | +0.6% | €5.476 | €5.476 | €5.476 | 0 | |
| €5.445 | +0.169 | +3.2% | €5.445 | €5.445 | €5.445 | 0 | |
| €5.276 | +0.264 | +5.3% | €5.276 | €5.276 | €5.276 | 0 | |
| €5.012 | +0.187 | +3.9% | €5.012 | €5.012 | €5.012 | 0 | |
| €4.825 | -0.167 | -3.3% | €4.825 | €4.825 | €4.825 | 0 | |
| €4.992 | -0.294 | -5.6% | €5.078 | €5.084 | €4.958 | 550 | |
| €5.286 | +0.019 | +0.4% | €5.286 | €5.286 | €5.286 | 0 | |
| €5.267 | -0.081 | -1.5% | €5.267 | €5.267 | €5.267 | 1,000 | |
| €5.348 | -0.153 | -2.8% | €5.348 | €5.348 | €5.348 | 0 | |
| €5.501 | +0.195 | +3.7% | €5.501 | €5.501 | €5.501 | 0 | |
| €5.306 | +0.12 | +2.3% | €5.306 | €5.306 | €5.306 | 0 | |
| €5.186 | +0.013 | +0.3% | €5.186 | €5.186 | €5.186 | 0 | |
| €5.173 | +0.146 | +2.9% | €5.088 | €5.206 | €5.063 | 80 | |
| €5.027 | -0.07 | -1.4% | €5.027 | €5.027 | €5.027 | 0 | |
| €5.097 | +0.346 | +7.3% | €5.097 | €5.097 | €5.097 | 0 | |
| €4.751 | +0.324 | +7.3% | €4.751 | €4.751 | €4.751 | 0 | |
| €4.427 | +0.098 | +2.3% | €4.427 | €4.427 | €4.427 | 0 | |
| €4.329 | +0.207 | +5.0% | €4.329 | €4.329 | €4.329 | 300 | |
| €4.122 | -0.03 | -0.7% | €4.122 | €4.122 | €4.122 | 0 | |
| €4.152 | +0.211 | +5.4% | €4.152 | €4.152 | €4.152 | 0 |
- Ticker
- Frankfurt:ER4
- Asset type
- Stock
- Sector
- Health care
- Industry
- Pharmaceuticals
- Exchange
- Frankfurt
- Currency
- EUR
What changed lately
Latest news release · Nov 16, 2026
Asimov and Emergent Biosolutions Announce Cell Line Development Partnership to Advance Novel Antibodies Against Ebola
Latest earnings call · Nov 2, 2026
Emergent BioSolutions (NYSE:EBS) Q3 2026 Earnings Call
Replay and transcript
Latest deck · Nov 2, 2026
Q3 2026 Earnings Presentation
Earnings · 35 slides
Latest news
Emergent BioSolutions Receives $22.3 Million Delivery Order Modification to Supply BioThrax® (Anthrax Vaccine Adsorbed) to the U.S. Department of War
Nov 4, 2026
Closed €5.25 (-4.4%) on Nov 5, 2026
Emergent BioSolutions Announces Retirement of Chief Financial Officer Richard S. Lindahl
Oct 16, 2026
Closed €6.34 (+4.2%) on Oct 16, 2026
Emergent BioSolutions to Report Third Quarter 2026 Financial Results on November 2, 2026
Oct 15, 2026
Closed €6.08 (-0.5%) on Oct 15, 2026
Media Advisory: Emergent to Host Ribbon Cutting Ceremony at Canton Manufacturing Facility
Sep 15, 2026
Closed €5.45 (+3.2%) on Sep 15, 2026
Emergent BioSolutions Completes Repurchase of $75 Million Aggregate Principal Amount of Senior Unsecured Notes
Sep 3, 2026
Closed €5.50 (+3.7%) on Sep 3, 2026
Emergent BioSolutions Awarded Contract Modification Valued at Approximately $24 Million for CYFENDUS® (Anthrax Vaccine Adsorbed, Adjuvanted)
Sep 1, 2026
Closed €5.19 (+0.3%) on Sep 1, 2026
Emergent BioSolutions Awarded Government of Canada Standing Offer for NARCAN® Nasal Spray
Aug 31, 2026
Closed €5.17 (+2.9%) on Aug 31, 2026
Emergent BioSolutions Reinforces Commitment to Opioid Overdose Education and Preparedness on International Overdose Awareness Day
Aug 31, 2026
Closed €5.17 (+2.9%) on Aug 31, 2026
Emergent BioSolutions Inc. on 6ix
- Sector
- Health care
- Industry
- Pharmaceuticals
- News releases
- 36 in the last 12 months · 70 in all · newest Nov 16, 2026 · oldest 2025
- Calls
- 26 calls with a replay · 26 with a transcript · latest Nov 2, 2026
- Decks
- 46 decks · latest Nov 2, 2026
Where Emergent BioSolutions Inc. is listed
| Listing | Exchange | Country | Currency |
|---|---|---|---|
| NYSE:EBS · Home listing | NYSE | United States | USD |
| gettex:ER4 | gettex | Germany | EUR |
| Stuttgart:ER4 | Stuttgart | Germany | EUR |
| Tradegate:ER4 | Tradegate | Germany | EUR |
| Lang & Schwarz:A0LC2W | Lang & Schwarz | Germany | EUR |
| LS Exchange:A0LC2W | LS Exchange | Germany | EUR |
| LSE:0IGA | LSE | United Kingdom | USD |
| Frankfurt:ER4 · This page | Frankfurt | Germany | EUR |
| BOATS:EBS | BOATS | United States | USD |
| BX Swiss:ER4 | BX Swiss | Switzerland | CHF |
| Dusseldorf:ER4 | Dusseldorf | Germany | EUR |
| Munich:ER4 | Munich | Germany | EUR |
Valuation
EV/sales 0.9× against a median of 2.2×: 2nd lowest of 11 Pharmaceuticals companies shown. Statements: 4 quarters to Sep 30, 2026 · price Nov 20, 2026
- Enterprise value
- $598.2M USD
- P/E
- Loss
- EV/sales
- 0.9×
- EV/EBITDA
- Negative EBITDA
- Price/book
- 0.8×
- Gross margin
- 48.4%
- Operating margin
- −27.7%
- Net margin
- −40.2%
- Debt to equity
- 1.6×
- Beta vs S&P 500
- 1.17
Pharmaceuticals: the 10 companies nearest in size, of 492 on 6ix with figures. Size in US dollars.
| Company | Mkt cap | EV | P/E | EV/Sales | EV/EBITDA | P/B | Net mgn | Debt/Eq | Beta |
|---|---|---|---|---|---|---|---|---|---|
| Emergent BioSolutions Inc. · NYSE:EBS | US$259.6M | US$598.2M | n/a | 0.9× | n/a | 0.8× | −40.2% | 1.6× | 1.17 |
| Deva Holding A.S. · BIST:DEVA | US$276.8M | US$244.9M | n/a | 0.6× | 4.4× | 0.4× | −3.9% | 0.1× | n/a |
| Honz Pharmaceutical Co., Ltd. Class A · SZSE:300086 | US$276.0M | US$298.2M | n/a | 5.9× | n/a | 2.2× | −62.4% | 0.2× | n/a |
| Shandong Sito Bio-technology Co., Ltd. Class A · SZSE:300583 | US$272.2M | US$254.6M | 62.3× | 1.5× | n/a | 1.0× | 2.6% | 0.1× | n/a |
| Lavipharm SA · ATHEX:LAVI | US$271.0M | US$309.1M | 41.2× | 4.5× | 22.8× | 4.4× | 9.6% | 0.7× | n/a |
| Zhejiang East Asia Pharmaceutical Co., Ltd. Class A · SSE:605177 | US$264.1M | US$340.3M | n/a | 2.4× | n/a | 1.1× | −21.8% | 0.5× | n/a |
| Jilin Jian Yisheng Pharmaceutical Co., Ltd. Class A · SZSE:002566 | US$260.3M | US$189.9M | 66.4× | 2.1× | n/a | 0.8× | 4.4% | 0.1× | n/a |
| Hua Medicine Ltd. · HKEX:2552 | US$256.7M | US$148.9M | 1.6× | 2.1× | n/a | 1.7× | 224.4% | 0.4× | n/a |
| Antibiotice SA · BVB:ATB | US$256.3M | US$267.7M | 154× | 2.1× | 16.9× | 1.3× | 1.3% | 0.1× | n/a |
| Shanxi C&Y Pharmaceutical Group Co., Ltd. Class A · SZSE:300254 | US$256.0M | US$273.8M | 76.4× | 2.3× | n/a | 3.4× | 2.8% | 0.5× | n/a |
| Protalix BioTherapeutics, Inc. (de) · AMEX:PLX | US$244.5M | US$205.1M | 11.9× | 2.4× | 7.7× | 3.0× | 24.3% | 0.1× | 1.05 |
| Median of the others | US$262.2M | US$261.1M | 62.3× | 2.2× | 12.3× | 1.5× | 2.7% | 0.1× | 1.05 |
Forecasts
2 strong buy · 1 sell · Analysts' consensus from EODHD, read Nov 16, 2026. Not 6ix's view and not investment advice.
- Price target
- 10.00 USD · Analysts' mean
- EPS, year to Dec 2026
- 0.29 · 2 analysts
- Revenue, year to Dec 2026
- 646.8M · 3 analysts
Team and board
Officers
| Officer | Role |
|---|---|
| Joseph Papa | President and Chief Executive Officer |
| Jessica Perl | Senior Vice President, General Counsel and Corporate Secretary |
| Bill Hartzel | Senior Vice President, Manufacturing and Bioservices |
| Coleen Glessner | Executive Vice President Quality and Ethics and Compliance |
| Michelle Pepin | Senior Vice President and Chief Human Resources Officer |
| Paul Williams | Senior Vice President, Products Business |
| Richard S. Lindahl | Executive Vice President |
| Stephanie Duatschek | Executive Vice President, Chief Growth Officer |
Board
| Director | Role |
|---|---|
| Zsolt Harsanyi | Independent Director, Chairman of the Board |
| Don DeGolyer | Independent Director |
| John D. Fowler | Independent Director |
| Kathryn C. Zoon | Independent Director |
| Kay Niedzwiecki | Director |
| Keith Katkin | Independent Director |
| Marvin White | Independent Director |
| Neal Fowler | Independent Director |
| Ronald B. Richard | Independent Director |
| Sujata Dayal | Independent Director |
Events
Calls
| Call | When | Status |
|---|---|---|
| Emergent BioSolutions (NYSE:EBS) Q3 2026 Earnings Call | Mon, Nov 02, 2026 · 5:00 PM ET | Replay |
| Emergent BioSolutions (NYSE:EBS) Q2 2026 Earnings Call | Wed, Aug 05, 2026 · 5:00 PM ET | Replay |
| Emergent BioSolutions (NYSE:EBS) Q1 2026 Earnings Call | Thu, Apr 30, 2026 · 5:00 PM ET | Replay |
| Emergent BioSolutions (NYSE:EBS) Q4 2025 Earnings Call | Thu, Feb 26, 2026 · 5:00 PM ET | Replay |
| Emergent BioSolutions (NYSE:EBS) Q3 2025 Earnings Call | Wed, Oct 29, 2025 · 5:00 PM ET | Replay |
| Emergent BioSolutions (NYSE:EBS) Q2 2025 Earnings Call | Wed, Aug 06, 2025 · 5:00 PM ET | Replay |
| Emergent BioSolutions (NYSE:EBS) Q1 2025 Earnings Call | Wed, May 07, 2025 · 5:00 PM ET | Replay |
| Emergent BioSolutions (NYSE:EBS) Q4 2024 Earnings Call | Tue, Mar 04, 2025 · 4:00 AM ET | Replay |
| Emergent BioSolutions (NYSE:EBS) Q3 2024 Earnings Call | Wed, Nov 06, 2024 · 5:00 PM ET | Replay |
| Emergent BioSolutions (NYSE:EBS) Q2 2024 Earnings Call | Tue, Aug 06, 2024 · 5:00 PM ET | Replay |
All 26 calls
Results days
| Quarter | Results | Share move |
|---|---|---|
| Q3 2026 | Nov 2, 2026 · After close | −3.0% |
| Q2 2026 | Aug 5, 2026 · After close | −29.6% |
| Q1 2026 | Apr 30, 2026 · After close | +2.9% |
| Q4 2025 | Feb 26, 2026 | −26.0% |
| Q3 2025 | Oct 29, 2025 · After close | +36.6% |
| Q2 2025 | Aug 6, 2025 · After close | +36.6% |
| Q1 2025 | May 7, 2025 · After close | +34.2% |
| Q4 2024 | Mar 4, 2025 · Before open | −6.4% |
| Q3 2024 | Nov 6, 2024 · After close | +19.6% |
| Q2 2024 | Aug 6, 2024 · After close | −42.0% |
All 20 quarters
| Quarter | Results | Share move |
|---|---|---|
| Q1 2024 | May 1, 2024 · After close | +71.0% |
| Q4 2023 | Mar 6, 2024 · After close | −15.0% |
| Q3 2023 | Dec 11, 2023 · Before open | −14.9% |
| Q2 2023 | Aug 8, 2023 · After close | −17.8% |
| Q1 2023 | May 9, 2023 · After close | +11.4% |
| Q4 2022 | Feb 27, 2023 · After close | −11.6% |
| Q3 2022 | Nov 8, 2022 · After close | −34.9% |
| Q2 2022 | Aug 1, 2022 · After close | −11.6% |
| Q1 2022 | Apr 28, 2022 · After close | −11.6% |
| Q4 2021 | Feb 24, 2022 · After close | −6.4% |
Decks
| Deck | Kind | Slides | Date |
|---|---|---|---|
| Q3 2026 Earnings Presentation | Earnings | 35 slides | Nov 2, 2026 |
| H.C. Wainwright 28th Annual Global Investment Conference (September 2026) | Conference | 31 slides | Sep 14, 2026 |
| Q2 2026 Earnings Presentation | Earnings | 34 slides | Aug 5, 2026 |
| Q1 2026 Earnings Presentation | Earnings | 36 slides | Apr 30, 2026 |
| Q4 2025 Earnings Presentation | Earnings | 40 slides | Feb 26, 2026 |
| 44th Annual J.P. Morgan Healthcare Conference (January 2026) | Conference | 21 slides | Jan 14, 2026 |
| Q3 2025 Earnings Presentation | Earnings | 36 slides | Oct 29, 2025 |
| Q2 2025 Earnings Presentation | Earnings | 32 slides | Aug 6, 2025 |
| Q1 2025 Earnings Presentation | Earnings | 31 slides | May 7, 2025 |
| Q4 2024 Earnings Presentation | Earnings | 40 slides | Mar 4, 2025 |
All 46 decks
Financials
Annual, in USD
Income statement
| Line | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 | FY2018 | FY2017 | FY2016 |
|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | 742.9M | 1.04B | 1.05B | 1.12B | 1.77B | 1.58B | 1.11B | 782.4M | 560.9M | 488.8M |
| Cost of revenue | 326.2M | 681.3M | 705.4M | 693.1M | 748.1M | 537.0M | 433.5M | 322.3M | 187.7M | 126.3M |
| Gross profit | 416.7M | 362.3M | 317.6M | 383.0M | 891.3M | 925.2M | 672.5M | 460.1M | 373.2M | 362.5M |
| Research and development | 53.2M | 70.7M | 111.4M | 188.3M | 235.2M | 237.9M | 226.2M | 142.8M | 97.4M | 106.9M |
| Selling, general and administrative | 186.1M | 308.0M | 368.4M | 339.5M | 348.7M | 304.1M | 273.5M | 202.5M | 142.9M | 143.1M |
| Operating income | 100.1M | -108.7M | -726.4M | -170.0M | 341.4M | 438.5M | 114.1M | 89.8M | 124.3M | 105.5M |
| Depreciation and amortization | 95.8M | 108.8M | 125.1M | 143.3M | 123.8M | 50.1M | 49.5M | 36.3M | 32.2M | 28.0M |
| EBITDA | 195.9M | 100.0K | -601.3M | -26.7M | 465.2M | 488.6M | 163.6M | 126.1M | 156.5M | 133.5M |
| Interest expense | 59.3M | 71.0M | 87.9M | 37.3M | 34.5M | 31.3M | 38.4M | 9.90M | 6.60M | 7.60M |
| Income before tax | 82.8M | -142.9M | -731.2M | -219.0M | 303.2M | 411.9M | 77.4M | 81.5M | 118.6M | 99.2M |
| Income tax | 30.2M | 47.7M | 29.3M | -7.40M | 83.7M | 106.1M | 22.9M | 18.8M | 36.0M | 36.7M |
| Net income | 52.6M | -190.6M | -760.5M | -211.6M | 219.5M | 305.8M | 54.5M | 62.7M | 82.6M | 51.8M |
| Earnings per share, basic | 0.98 | -3.60 | -14.85 | -4.22 | 4.10 | 5.80 | 1.06 | 1.25 | 1.98 | 1.29 |
| Earnings per share, diluted | 0.93 | -3.60 | -14.85 | -4.22 | 4.06 | 5.68 | 1.04 | 1.22 | 1.71 | 1.13 |
Balance sheet
| Line | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 | FY2018 | FY2017 | FY2016 |
|---|---|---|---|---|---|---|---|---|---|---|
| Cash and equivalents | 205.4M | 99.5M | 111.7M | 642.6M | 576.1M | 621.3M | 167.8M | 112.2M | 178.3M | 271.5M |
| Receivables | 84.2M | 154.5M | 191.0M | 159.2M | 278.9M | 230.9M | 270.7M | 262.5M | 143.7M | 138.5M |
| Inventory | 343.4M | 311.7M | 328.9M | 350.7M | 344.5M | 307.0M | 222.5M | 205.8M | 142.8M | 74.0M |
| Current assets | 662.5M | 598.7M | 679.5M | 1.21B | 1.27B | 1.20B | 686.2M | 620.8M | 485.4M | 510.2M |
| Property, plant and equipment | 205.4M | 270.6M | 382.8M | 817.6M | 800.1M | 644.1M | 542.3M | 510.2M | 407.2M | 376.4M |
| Goodwill | 0 | 0 | 0 | 218.2M | 224.9M | 266.7M | 266.6M | 259.7M | 49.1M | 41.0M |
| Total assets | 1.32B | 1.39B | 1.82B | 3.17B | 2.96B | 2.88B | 2.33B | 2.23B | 1.07B | 970.1M |
| Accounts payable | 55.6M | 60.9M | 112.2M | 103.5M | 128.9M | 136.1M | 94.8M | 80.7M | 41.8M | 34.6M |
| Current liabilities | 132.2M | 162.4M | 651.3M | 1.23B | 374.0M | 384.5M | 216.3M | 200.4M | 100.1M | 105.9M |
| Long-term debt | 572.1M | 663.7M | 446.5M | 448.5M | 809.4M | 841.0M | 798.4M | 784.5M | 13.5M | 248.1M |
| Total debt | 589.7M | 700.0M | 868.4M | 1.41B | 849.6M | 885.5M | 822.5M | 808.8M | 13.6M | 248.1M |
| Total liabilities | 796.0M | 906.9M | 1.17B | 1.78B | 1.35B | 1.44B | 1.24B | 1.22B | 157.9M | 373.9M |
| Shareholders' equity | 522.6M | 482.8M | 649.3M | 1.39B | 1.61B | 1.45B | 1.09B | 1.01B | 912.3M | 596.2M |
| Shares outstanding | 52.1M | 54.3M | 52.2M | 50.1M | 51.3M | 53.1M | 51.7M | 51.2M | 49.4M | 40.6M |
Cash flow
| Line | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 | FY2018 | FY2017 | FY2016 |
|---|---|---|---|---|---|---|---|---|---|---|
| Cash from operations | 170.6M | 58.7M | -206.3M | -34.1M | 320.2M | 536.9M | 188.0M | 41.8M | 208.1M | 54.6M |
| Capital spending | -13.8M | -22.9M | -51.6M | -115.8M | -224.1M | -141.9M | -86.9M | -72.1M | -54.8M | -76.2M |
| Free cash flow | 156.8M | 35.8M | -257.9M | -149.9M | 96.1M | 395.0M | 101.1M | -30.3M | 153.3M | -21.6M |
| Cash from investing | 69.4M | 125.2M | 212.3M | -381.3M | -224.1M | -151.9M | -96.9M | -897.2M | -249.9M | -76.2M |
| Cash from financing | -136.6M | -190.0M | -535.7M | 481.2M | -141.0M | 69.5M | -35.9M | 788.7M | -51.4M | -19.8M |
| Share buybacks | -24.9M | 0 | 0 | -82.1M | -106.0M | 0 | 0 | -100.0K | -33.1M | 0 |
| Change in cash | 103.5M | -6.10M | -530.9M | 66.3M | -45.2M | 453.5M | 55.6M | -66.9M | -93.2M | -41.3M |
Filings
| Filing | Date | Type | Filed with |
|---|---|---|---|
| SCHEDULE 13G/A · Big-stake notice, amended | Nov 16, 2026 | Big-stake notice | SEC |
| SCHEDULE 13G/A · Big-stake notice, amended | Nov 16, 2026 | Big-stake notice | SEC |
| 8-K · Current report | Nov 4, 2026 | Current report | SEC |
| 10-Q · Quarterly report | Nov 2, 2026 | Quarterly report | SEC |
| 8-K · Current report | Nov 2, 2026 | Results | SEC |
| 8-K · Current report | Oct 16, 2026 | Management or board change | SEC |
| 144 · Notice of proposed sale | Oct 7, 2026 | Other filings | SEC |
| 4 · Change in ownership | Oct 7, 2026 | Insider trade | SEC |
| 4 · Change in ownership | Oct 5, 2026 | Insider trade | SEC |
| 144 · Notice of proposed sale | Oct 1, 2026 | Other filings | SEC |
Show 200 filings
| Filing | Date | Type | Filed with |
|---|---|---|---|
| 8-K · Current report | Sep 14, 2026 | Current report | SEC |
| 8-K · Current report | Sep 1, 2026 | Current report | SEC |
| SCHEDULE 13G · Big-stake notice | Aug 14, 2026 | Big-stake notice | SEC |
| 3 · Initial statement of ownership | Aug 12, 2026 | Insider trade | SEC |
| 10-Q · Quarterly report | Aug 5, 2026 | Quarterly report | SEC |
| 8-K · Current report | Aug 5, 2026 | Results | SEC |
| SCHEDULE 13G/A · Big-stake notice, amended | Jul 31, 2026 | Big-stake notice | SEC |
| SCHEDULE 13G/A · Big-stake notice, amended | Jul 28, 2026 | Big-stake notice | SEC |
| 4 · Change in ownership | Jul 2, 2026 | Insider trade | SEC |
| 144 · Notice of proposed sale | Jul 1, 2026 | Other filings | SEC |
| 8-K · Current report | Jun 29, 2026 | Material contract | SEC |
| 4 · Change in ownership | Jun 10, 2026 | Insider trade | SEC |
| 4 · Change in ownership | Jun 10, 2026 | Insider trade | SEC |
| 4 · Change in ownership | Jun 10, 2026 | Insider trade | SEC |
| 4 · Change in ownership | Jun 10, 2026 | Insider trade | SEC |
| 4 · Change in ownership | May 4, 2026 | Insider trade | SEC |
| 4 · Change in ownership | May 4, 2026 | Insider trade | SEC |
| 4 · Change in ownership | May 4, 2026 | Insider trade | SEC |
| 4 · Change in ownership | May 4, 2026 | Insider trade | SEC |
| 4 · Change in ownership | May 4, 2026 | Insider trade | SEC |
| 4 · Change in ownership | May 4, 2026 | Insider trade | SEC |
| 4 · Change in ownership | May 4, 2026 | Insider trade | SEC |
| 4 · Change in ownership | May 4, 2026 | Insider trade | SEC |
| 4 · Change in ownership | May 4, 2026 | Insider trade | SEC |
| 4 · Change in ownership | May 1, 2026 | Insider trade | SEC |
| 4 · Change in ownership | May 1, 2026 | Insider trade | SEC |
| 4 · Change in ownership | May 1, 2026 | Insider trade | SEC |
| 4 · Change in ownership | May 1, 2026 | Insider trade | SEC |
| 4 · Change in ownership | May 1, 2026 | Insider trade | SEC |
| 4 · Change in ownership | May 1, 2026 | Insider trade | SEC |
| 4 · Change in ownership | May 1, 2026 | Insider trade | SEC |
| 144 · Notice of proposed sale | May 1, 2026 | Other filings | SEC |
| 144 · Notice of proposed sale | May 1, 2026 | Other filings | SEC |
| 144 · Notice of proposed sale | May 1, 2026 | Other filings | SEC |
| 10-Q · Quarterly report | Apr 30, 2026 | Quarterly report | SEC |
| S-8 · Registration statement for employee plans | Apr 30, 2026 | Offer document | SEC |
| 8-K · Current report | Apr 30, 2026 | Results | SEC |
| 144 · Notice of proposed sale | Apr 30, 2026 | Other filings | SEC |
| 8-K · Current report | Apr 30, 2026 | Meeting outcome | SEC |
| SCHEDULE 13G · Big-stake notice | Apr 29, 2026 | Big-stake notice | SEC |
| DEFA14A · Additional proxy material | Apr 28, 2026 | Meeting notice | SEC |
| DEFA14A · Additional proxy material | Apr 27, 2026 | Meeting notice | SEC |
| DEFA14A · Additional proxy material | Apr 22, 2026 | Meeting notice | SEC |
| 8-K · Current report | Apr 16, 2026 | Material contract | SEC |
| DEFA14A · Additional proxy material | Apr 16, 2026 | Meeting notice | SEC |
| DEFA14A · Additional proxy material | Apr 16, 2026 | Meeting notice | SEC |
| SCHEDULE 13G · Big-stake notice | Apr 9, 2026 | Big-stake notice | SEC |
| 4 · Change in ownership | Apr 3, 2026 | Insider trade | SEC |
| 144 · Notice of proposed sale | Apr 1, 2026 | Other filings | SEC |
| SCHEDULE 13G/A · Big-stake notice, amended | Mar 26, 2026 | Big-stake notice | SEC |
| ARS · Annual report to shareholders | Mar 20, 2026 | Annual report | SEC |
| DEFA14A · Additional proxy material | Mar 20, 2026 | Meeting notice | SEC |
| DEF 14A · Proxy statement | Mar 20, 2026 | Meeting notice | SEC |
| 4 · Change in ownership | Mar 6, 2026 | Insider trade | SEC |
| 4 · Change in ownership | Mar 5, 2026 | Insider trade | SEC |
| 4 · Change in ownership | Mar 5, 2026 | Insider trade | SEC |
| 3 · Initial statement of ownership | Mar 5, 2026 | Insider trade | SEC |
| 4 · Change in ownership | Mar 5, 2026 | Insider trade | SEC |
| 4 · Change in ownership | Mar 5, 2026 | Insider trade | SEC |
| 4 · Change in ownership | Mar 5, 2026 | Insider trade | SEC |
| 4 · Change in ownership | Mar 5, 2026 | Insider trade | SEC |
| 4 · Change in ownership | Mar 5, 2026 | Insider trade | SEC |
| 4 · Change in ownership | Mar 5, 2026 | Insider trade | SEC |
| 4 · Change in ownership | Mar 3, 2026 | Insider trade | SEC |
| 4 · Change in ownership | Mar 3, 2026 | Insider trade | SEC |
| 4 · Change in ownership | Mar 3, 2026 | Insider trade | SEC |
| 8-K · Current report | Mar 3, 2026 | Management or board change | SEC |
| 10-K · Annual report | Feb 26, 2026 | Annual report | SEC |
| 8-K · Current report | Feb 26, 2026 | Results | SEC |
| 4 · Change in ownership | Feb 10, 2026 | Insider trade | SEC |
| 4 · Change in ownership | Feb 10, 2026 | Insider trade | SEC |
| 4 · Change in ownership | Feb 10, 2026 | Insider trade | SEC |
| 4 · Change in ownership | Feb 10, 2026 | Insider trade | SEC |
| 4 · Change in ownership | Feb 10, 2026 | Insider trade | SEC |
| SCHEDULE 13G · Big-stake notice | Feb 9, 2026 | Big-stake notice | SEC |
| SCHEDULE 13G/A · Big-stake notice, amended | Jan 30, 2026 | Big-stake notice | SEC |
| 8-K · Current report | Jan 14, 2026 | Current report | SEC |
| 8-K · Current report | Jan 12, 2026 | Current report | SEC |
| 144 · Notice of proposed sale | Jan 7, 2026 | Other filings | SEC |
| 144 · Notice of proposed sale | Dec 22, 2025 | Other filings | SEC |
| 4 · Change in ownership | Dec 16, 2025 | Insider trade | SEC |
| 8-K · Current report | Dec 12, 2025 | Current report | SEC |
| 4 · Change in ownership | Dec 9, 2025 | Insider trade | SEC |
| 144 · Notice of proposed sale | Dec 5, 2025 | Other filings | SEC |
| 4 · Change in ownership | Nov 13, 2025 | Insider trade | SEC |
| 4 · Change in ownership | Nov 12, 2025 | Insider trade | SEC |
| 8-K · Current report | Nov 12, 2025 | Management or board change | SEC |
| 4 · Change in ownership | Nov 10, 2025 | Insider trade | SEC |
| 144 · Notice of proposed sale | Nov 10, 2025 | Other filings | SEC |
| 144 · Notice of proposed sale | Nov 7, 2025 | Other filings | SEC |
| 10-Q · Quarterly report | Oct 29, 2025 | Quarterly report | SEC |
| 8-K · Current report | Oct 29, 2025 | Results | SEC |
| 4 · Change in ownership | Oct 17, 2025 | Insider trade | SEC |
| 4 · Change in ownership | Oct 16, 2025 | Insider trade | SEC |
| 144 · Notice of proposed sale | Oct 7, 2025 | Other filings | SEC |
| 8-K · Current report | Sep 11, 2025 | Material contract | SEC |
| 8-K · Current report | Sep 5, 2025 | Current report | SEC |
| 4 · Change in ownership | Aug 18, 2025 | Insider trade | SEC |
| EFFECT · Notice that a registration is effective | Aug 18, 2025 | Other filings | SEC |
| 144 · Notice of proposed sale | Aug 15, 2025 | Other filings | SEC |
| 4 · Change in ownership | Aug 13, 2025 | Insider trade | SEC |
| CORRESP · Letter to the SEC | Aug 13, 2025 | Other filings | SEC |
| UPLOAD · Letter from the SEC | Aug 13, 2025 | Other filings | SEC |
| 144 · Notice of proposed sale | Aug 12, 2025 | Other filings | SEC |
| S-3 · Registration statement | Aug 7, 2025 | Offer document | SEC |
| 10-Q · Quarterly report | Aug 6, 2025 | Quarterly report | SEC |
| 8-K · Current report | Aug 6, 2025 | Results | SEC |
| SCHEDULE 13G · Big-stake notice | Jul 17, 2025 | Big-stake notice | SEC |
| 4 · Change in ownership | Jul 15, 2025 | Insider trade | SEC |
| 8-K · Current report | Jun 24, 2025 | Current report | SEC |
| 4 · Change in ownership | Jun 10, 2025 | Insider trade | SEC |
| 4 · Change in ownership | Jun 10, 2025 | Insider trade | SEC |
| 4 · Change in ownership | Jun 10, 2025 | Insider trade | SEC |
| 4 · Change in ownership | Jun 10, 2025 | Insider trade | SEC |
| 4 · Change in ownership | May 28, 2025 | Insider trade | SEC |
| 8-K · Current report | May 23, 2025 | Current report | SEC |
| 144 · Notice of proposed sale | May 23, 2025 | Other filings | SEC |
| 4 · Change in ownership | May 15, 2025 | Insider trade | SEC |
| 10-Q · Quarterly report | May 7, 2025 | Quarterly report | SEC |
| 8-K · Current report | May 7, 2025 | Results | SEC |
| 8-K · Current report | May 6, 2025 | Meeting outcome | SEC |
| 4 · Change in ownership | May 2, 2025 | Insider trade | SEC |
| 4 · Change in ownership | May 2, 2025 | Insider trade | SEC |
| 4 · Change in ownership | May 2, 2025 | Insider trade | SEC |
| 4 · Change in ownership | May 2, 2025 | Insider trade | SEC |
| 4 · Change in ownership | May 2, 2025 | Insider trade | SEC |
| 4 · Change in ownership | May 2, 2025 | Insider trade | SEC |
| 4 · Change in ownership | May 2, 2025 | Insider trade | SEC |
| 4 · Change in ownership | May 2, 2025 | Insider trade | SEC |
| 4 · Change in ownership | May 2, 2025 | Insider trade | SEC |
| 4 · Change in ownership | Apr 9, 2025 | Insider trade | SEC |
| 4 · Change in ownership | Apr 9, 2025 | Insider trade | SEC |
| 4/A · Change in ownership, amended | Apr 9, 2025 | Insider trade | SEC |
| 8-K · Current report | Mar 31, 2025 | Current report | SEC |
| EFFECT · Notice that a registration is effective | Mar 25, 2025 | Other filings | SEC |
| 424B3 · Prospectus | Mar 24, 2025 | Offer document | SEC |
| 8-K · Current report | Mar 21, 2025 | Current report | SEC |
| DEF 14A · Proxy statement | Mar 21, 2025 | Meeting notice | SEC |
| DEFA14A · Additional proxy material | Mar 21, 2025 | Meeting notice | SEC |
| ARS · Annual report to shareholders | Mar 21, 2025 | Annual report | SEC |
| 4 · Change in ownership | Mar 12, 2025 | Insider trade | SEC |
| 4 · Change in ownership | Mar 12, 2025 | Insider trade | SEC |
| 4 · Change in ownership | Mar 12, 2025 | Insider trade | SEC |
| 144 · Notice of proposed sale | Mar 12, 2025 | Other filings | SEC |
| 144 · Notice of proposed sale | Mar 12, 2025 | Other filings | SEC |
| 8-K · Current report | Mar 10, 2025 | Current report | SEC |
| 4 · Change in ownership | Mar 10, 2025 | Insider trade | SEC |
| 4 · Change in ownership | Mar 10, 2025 | Insider trade | SEC |
| 4 · Change in ownership | Mar 10, 2025 | Insider trade | SEC |
| 4 · Change in ownership | Mar 10, 2025 | Insider trade | SEC |
| 4 · Change in ownership | Mar 10, 2025 | Insider trade | SEC |
| 4 · Change in ownership | Mar 10, 2025 | Insider trade | SEC |
| 4 · Change in ownership | Mar 10, 2025 | Insider trade | SEC |
| 4 · Change in ownership | Mar 7, 2025 | Insider trade | SEC |
| POS AM · Amendment to an effective registration | Mar 4, 2025 | Offer document | SEC |
| POS EX | Mar 4, 2025 | Other filings | SEC |
| 424B3 · Prospectus | Mar 4, 2025 | Offer document | SEC |
| 4 · Change in ownership | Mar 4, 2025 | Insider trade | SEC |
| 4 · Change in ownership | Mar 4, 2025 | Insider trade | SEC |
| 4 · Change in ownership | Mar 4, 2025 | Insider trade | SEC |
| 10-K · Annual report | Mar 3, 2025 | Annual report | SEC |
| 8-K · Current report | Mar 3, 2025 | Results | SEC |
| 4 · Change in ownership | Feb 11, 2025 | Insider trade | SEC |
| 8-K · Current report | Jan 15, 2025 | Current report | SEC |
| 8-K · Current report | Jan 14, 2025 | Current report | SEC |
| 8-K · Current report | Jan 8, 2025 | Current report | SEC |
| 4 · Change in ownership | Dec 17, 2024 | Insider trade | SEC |
| 4 · Change in ownership | Dec 10, 2024 | Insider trade | SEC |
| EFFECT · Notice that a registration is effective | Dec 5, 2024 | Other filings | SEC |
| 424B3 · Prospectus | Dec 4, 2024 | Offer document | SEC |
| CORRESP · Letter to the SEC | Dec 2, 2024 | Other filings | SEC |
| S-1/A · Registration statement, amended | Dec 2, 2024 | Offer document | SEC |
| 3 · Initial statement of ownership | Nov 21, 2024 | Insider trade | SEC |
| UPLOAD · Letter from the SEC | Nov 18, 2024 | Other filings | SEC |
| 4 · Change in ownership | Nov 14, 2024 | Insider trade | SEC |
| 4 · Change in ownership | Nov 13, 2024 | Insider trade | SEC |
| 4 · Change in ownership | Nov 13, 2024 | Insider trade | SEC |
| SC 13G · Big-stake notice | Nov 13, 2024 | Big-stake notice | SEC |
| 144 · Notice of proposed sale | Nov 12, 2024 | Other filings | SEC |
| 3 · Initial statement of ownership | Nov 12, 2024 | Insider trade | SEC |
| S-1 · Registration statement | Nov 12, 2024 | Offer document | SEC |
| 144 · Notice of proposed sale | Nov 12, 2024 | Other filings | SEC |
| SC 13G/A · Big-stake notice, amended | Nov 8, 2024 | Big-stake notice | SEC |
| 10-Q · Quarterly report | Nov 6, 2024 | Quarterly report | SEC |
| 8-K · Current report | Nov 6, 2024 | Results | SEC |
| 4 · Change in ownership | Oct 17, 2024 | Insider trade | SEC |
| 8-K · Current report | Oct 4, 2024 | Management or board change | SEC |
| 8-K · Current report | Oct 2, 2024 | Results | SEC |
| 8-K · Current report | Sep 17, 2024 | Financing | SEC |
| SC 13G/A · Big-stake notice, amended | Sep 10, 2024 | Big-stake notice | SEC |
This page holds 200 of 1,000 filings. Open Filings
Cap table
Built by 6ix from Emergent BioSolutions Inc.’s releases · as of Oct 26, 2026
- Common shares
- 51,415,182
- Fully diluted
- 51,415,182
Fully diluted
| Line | Shares | As of |
|---|---|---|
| Common shares | 51,415,182 | Oct 26, 2026 |
Share count over time
| Count | Shares |
|---|---|
| Oct 26, 2026 | 51,415,182 |
People
6ix reads each seat by machine from the page it links to, and can misread one.
| Person | Seat |
|---|---|
| Karen Smith Other companies: Context Therapeutics Inc. (Independent Director · Since at least Sep 4, 2024); Skye Bioscience, Inc. (Director · Since at least Jul 2, 2024); Sangamo Therapeutics, Inc. (Director · Since at least Jun 26, 2018); Aurinia Pharmaceuticals Inc (Director · Aug 18, 2023 – Nov 21, 2024 · Past); Quince Therapeutics, Inc. (Chief Medical Officer · May 19, 2022 – Feb 1, 2023 · Past); Tourmaline Bio Inc. (Director · May 16, 2022 – Jun 13, 2023 · Past); Antares Pharma Inc (Director · Mar 1, 2019 – May 24, 2022 · Past); Acceleron Pharma Inc (Director · Nov 15, 2017 – Nov 19, 2021 · Past); Sucampo Pharmaceuticals Inc (Director · Jul 15, 2017 – Feb 13, 2018 · Past); Jazz Pharmaceuticals plc (EVP, R&D and CMO · Apr 13, 2015 – Mar 5, 2018 · Past) | EVP, Chief Medical Officer · May 21, 2020 – May 7, 2021 · Past |
| Louis W Sullivan Other companies: United Therapeutics Corporation (Director · Since at least Jun 26, 2006); ANI Pharmaceuticals, Inc. (Director · Mar 16, 2006 – Mar 30, 2012 · Past); Henry Schein, Inc. (Director · Mar 2, 2006 – Mar 31, 2016 · Past); Inhibitex Inc (Director · Feb 1, 2006 – Feb 1, 2007 · Past); 3M Company (Director · Dec 31, 2005 – May 9, 2006 · Past); The Cigna Group (Director · Dec 31, 2005 – Jun 1, 2006 · Past); Bristol-Myers Squibb Company (Director · Dec 30, 2005 – Mar 31, 2006 · Past) | Director · Nov 14, 2006 – Apr 30, 2025 · Past |
| Joseph Papa Other companies: Milestone Pharmaceuticals Inc. (Independent Non-Executive Director · Since at least Sep 3, 2024); Candel Therapeutics, Inc. (Chairman · Since at least Aug 8, 2022); Bausch + Lomb Corporation (See Remarks, Director · May 5, 2022 – May 5, 2022 · Past); Prometheus Biosciences Inc (Director · Mar 11, 2021 – Jun 16, 2023 · Past); Bausch Health Companies Inc. (Director · May 2, 2016 – May 10, 2022 · Past); Perrigo Company plc (Director · Oct 9, 2006 – Feb 26, 2016 · Past) | President and Chief Executive Officer · Since at least Feb 21, 2024 |
| Keith A. Katkin Other companies: Eledon Pharmaceuticals, Inc. (Chairman of the Board of Directors · Since at least May 10, 2017); Syndax Pharmaceuticals, Inc. (Director · Since at least Mar 29, 2017); Urovant Sciences Ltd (PEO;CEO/Urovant Sciences, Inc., Director · Sep 26, 2018 – Feb 19, 2020 · Past); Rigel Pharmaceuticals, Inc. (Director · Jun 29, 2015 – May 19, 2021 · Past); Carbylan Therapeutics Inc (Director · Apr 8, 2015 – Aug 3, 2015 · Past); Avanir Pharmaceuticals Inc (President and CEO, Director · May 15, 2013 – Dec 15, 2014 · Past) | Independent Director · Since at least Apr 1, 2022 |
| Barry Labinger Other companies: Checkmate Pharmaceuticals Inc (President and CEO, Director · Aug 6, 2020 – Aug 4, 2021 · Past); Anadys Pharmaceuticals Inc (Director · Mar 11, 2011 – May 27, 2011 · Past); Human Genome Sciences Inc (Exec VP & CCO · Mar 14, 2006 – Jul 30, 2012 · Past) | EVP, Biosciences Div. · Aug 12, 2013 – Nov 13, 2015 · Past |
| Marvin L. White Other companies: Aptevo Therapeutics Inc. (Executive Chair · Since at least Jul 29, 2016); CoLucid Pharmaceuticals Inc (Director · Jul 9, 2015 – Mar 1, 2017 · Past); Washington Prime Group Inc (Director · May 8, 2014 – Aug 4, 2014 · Past) | Independent Director · Since at least Jun 1, 2010 |
| Neal Fowler Other companies: Liquidia Corporation (Chief Executive Officer, Director · Nov 19, 2020 – Nov 19, 2020 · Past); Aralez Pharmaceuticals Inc (Director · Feb 5, 2016 – May 11, 2017 · Past); POZEN Inc (Director · Jun 10, 2010 – Jul 28, 2015 · Past) | Independent Director · Since at least Oct 1, 2023 |
| Richard S. Lindahl Other companies: Compass Therapeutics, Inc. (Executive Vice President, Chief Financial Officer and Treasurer, Emergent BioSolutions · Since at least Apr 21, 2023); The Corporate Executive Board Company (Chief Financial Officer · Mar 27, 2013 – Apr 27, 2015 · Past); SPRINT Corp (Treasurer · Feb 7, 2006 – Aug 4, 2008 · Past) | Executive Vice President · Since at least Mar 26, 2018 |
| Atul Saran Other companies: MacroGenics, Inc. (SVP & General Counsel · Jun 5, 2014 – Apr 28, 2017 · Past); Xencor, Inc. (Director · Dec 2, 2013 – Dec 6, 2013 · Past) | EVP, Chief Strat & Dev Officer · Jul 20, 2017 – Feb 28, 2023 · Past |
| Daniel J. Abdun-Nabi Other companies: Aptevo Therapeutics Inc. (President · Since at least Aug 1, 2016); Regenxbio Inc. (Director · Aug 5, 2016 – Jun 4, 2021 · Past) | CEO, Director · Nov 14, 2006 – Mar 4, 2019 · Past |
All 40 people
| Person | Seat |
|---|---|
| Fuad El-Hibri Other companies: Aptevo Therapeutics Inc. (Director · Aug 1, 2016 – Dec 3, 2021 · Past) | Director · Nov 14, 2006 – Dec 3, 2021 · Past |
| George A Joulwan Other companies: General Dynamics Corporation (Director · Jan 3, 2006 – Mar 12, 2012 · Past) | Director · Jul 17, 2013 – May 26, 2022 · Past |
| Jennifer Fox Other companies: Myriad Genetics, Inc. (Chief Legal Officer · Since at least Sep 3, 2024) | EVP, Ext Aff, GC, Corp Sec · Mar 1, 2022 – Jul 11, 2024 · Past |
| John D Fowler Jr Other companies: Beverly Enterprises Inc (Director · Mar 14, 2006 – Mar 14, 2006 · Past) | Director · Since at least Mar 1, 2026 |
| John E. Niederhuber Other companies: Aptevo Therapeutics Inc. (Lead Independent Director · Since at least Aug 1, 2016) | Director · Aug 23, 2010 – May 18, 2016 · Past |
| Robert Kramer Other companies: Aptevo Therapeutics Inc. (President, Director · Jul 15, 2016 – Jul 15, 2016 · Past) | President and CEO, Director · May 31, 2013 – Jun 9, 2023 · Past |
| Zsolt Harsanyi Other companies: Aptevo Therapeutics Inc. (Director · Since at least Jul 15, 2016) | Independent Director, Chairman of the Board · Since at least Nov 14, 2006 |
| Adam Havey | EVP, Business Operations · Mar 1, 2011 – Jun 9, 2023 · Past |
| Bill Hartzel | Senior Vice President, Manufacturing and Bioservices · Since at least Aug 8, 2023 |
| Coleen Glessner | Executive Vice President Quality and Ethics and Compliance · Since at least Mar 14, 2022 |
| Don DeGolyer | Director · Since at least Oct 1, 2023 |
| Edward Arcuri | COO · Nov 14, 2006 – May 8, 2007 · Past |
| H Haywood Miller III | Interim CEO · Jun 24, 2023 – Jun 24, 2023 · Past |
| Jerome M Hauer | Director · Nov 14, 2006 – May 25, 2023 · Past |
| Jessica Perl | Senior Vice President, General Counsel and Corporate Secretary · Since at least Oct 29, 2024 |
| John D. Fowler | Independent Director · Since at least Mar 3, 2026 |
| Katherine Strei | EVP, Chief HR Officer · Feb 27, 2018 – Feb 28, 2023 · Past |
| Kathryn C. Zoon | Independent Director · Since at least Nov 8, 2016 |
| Kay Niedzwiecki | Director · Since at least Nov 4, 2026 |
| Mauro Gibellini | SVP, Corporate Dev. · Apr 1, 2007 – Jun 4, 2007 · Past |
| Michelle Pepin | Senior Vice President and Chief Human Resources Officer · Since at least Nov 5, 2026 |
| Paul Williams | Senior Vice President, Products Business · Since at least Jan 9, 2023 |
| Ronald B. Richard | Independent Director · Since at least Oct 17, 2008 |
| Sean Kirk | EVP, Manufacturing & Tech Ops · Feb 25, 2020 – Mar 31, 2021 · Past |
| Simon C Lowry | SVP, R&D, CMO · Since at least Nov 18, 2024 |
| Stephanie Duatschek | Executive Vice President, Chief Growth Officer · Since at least Aug 5, 2026 |
| Steven Chatfield | EVP, BioSciences · Nov 14, 2006 – Mar 14, 2013 · Past |
| Sue Bailey | Director · Jun 14, 2007 – Mar 4, 2021 · Past |
| Sujata Dayal | Independent Director · Since at least Jul 15, 2022 |
| Thomas Zink | SVP & CMO · Nov 14, 2006 – May 17, 2007 · Past |
Log in to ask 6ix AI your own questions about Emergent BioSolutions Inc.